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New, better vaccines: the answer to the 
global tuberculosis epidemic
In 2010 tuberculosis (TB) disease occurred in an estimated 8.8 million 
persons globally, causing 1.45 million deaths.1 South Africa has not 
been spared: approximately 1% of our population develops TB disease 
every year.1 About 60% of our TB patients also have HIV infection, 
placing us at the epicentre of the TB/HIV co-epidemic.1 While the 
global TB incidence has dropped, including on the continent of 
Africa, our country’s disease rates have remained relatively static over 
the last few years.1
Advances in TB diagnosis and treatment are needed to control 
the epidemic.1,2 An effective vaccine would constitute the most 
sustainable intervention.1 The current TB vaccine, BCG, is important 
for prevention of severe forms of TB in infancy and early childhood, 
but affords variable efficacy – mostly poor – against lung TB. Adults 
with lung TB, particularly those who are not infected with HIV 
(Middelkoop et al., personal communication), spread the pathogen. 
Therefore new, better vaccination strategies should primarily aim to 
prevent disease in this population while including other populations 
at high risk of TB disease, such as infants/young children and HIV-
infected persons.
A brief history of SATVI
SATVI was founded in 2001. Initially known as the ‘BCG study unit’, 
it was located within the Child Health Unit of the School of Child 
and Adolescent Medicine of the University of Cape Town’s Faculty 
of Health Sciences. An immunology laboratory at Groote Schuur 
Hospital was later added to support core clinical trial activities.
A site for conducting clinical studies was established in the 
Boland Overberg region, about 110 km from Cape Town. The 
site’s research activities cover an area of about 40 000 km2, with a 
population of 350 000. Site selection has been critical for SATVI’s 
success, the primary determinant being high reported rates of TB, 
allowing end-points of vaccine trials to be achieved with reasonable 
sample sizes. Additionally, good transport, telecommunications 
and power infrastructure, availability of qualified or trainable staff 
and a relatively stable local population were essential, as also the 
well-functioning primary healthcare services, including adequate 
surveillance systems.
Operations at the field site are run from Brewelskloof Hospital 
in Worcester, a dedicated TB hospital for the region, and Worcester 
Hospital, a secondary level hospital. Two satellite site offices have 
been established, one in Robertson and one in Ceres.
The Cape Town operations of SATVI, including its state-of-the-
art immunology laboratory, are based at the Institute of Infectious 
Disease and Molecular Medicine at UCT’s Faculty of Health Sciences, 
where extensive human resource and information technology and 
data management infrastructure exist.
The personnel complement of SATVI has grown from 3 to more 
than 190 persons over 10 years, more than 20 000 participants have 
been enrolled into studies, funding support now exceeds R50 million 
a year, 80 research articles have been published in mid- to high-
impact journals, and multiple PhD, MSc and MPH candidates have 
graduated. SATVI leadership is represented on core international 
policy groups involved in TB vaccine development and in related, 
translational immunology. 
Clinical trials: BCG and new vaccines
The ‘BCG Trial’
Our initial project was a phase IV randomised clinical trial intended 
to assess whether the route of BCG administration to newborns 
determined efficacy in protecting against childhood TB. The study 
enrolled 11 680 infants at birth, over a period of 3.5 years, and 
showed equivalence in TB disease rates following BCG vaccination 
by an intradermal route and by a percutaneous route.3 This study 
was critical for developing infrastructure and capacity to conduct 
large-scale TB vaccine trials. The results may also guide policy in 
respect of BCG vaccination – it should be noted that the last clinical 
trial of a TB vaccine in infants was conducted by Rosenthal et al. in 
the 1930s and 1940s, long before the randomised placebo-controlled 
clinical trial came to be considered as the gold standard for evaluating 
vaccine interventions.4
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Trials of new TB vaccines
More than 40 TB vaccine candidates are in preclinical development; 
14 of these have entered human trials.5 New vaccines are likely to 
be administered within a heterologous prime boost strategy – using 
different vaccines to induce a first immune response and then boosting 
this immunity. The prime vaccine is likely to be a whole bacterium, 
which contains many antigens (which our immune systems recognise 
and react to), and can therefore induce broad immunity.
BCG is a classic prime vaccine. Novel prime vaccines in development 
include recombinant BCGs and even recombinant Mycobacterium 
tuberculosis (MTB). These viable organisms have been modified for 
greater safety, and to better induce an immune response important for 
protection against TB.
Current boost vaccines contain limited numbers of antigens, which 
are delivered either within a viral vector (vehicle) or together with 
specific adjuvants (see below). Viral-vectored boost vaccines use a 
modified cold virus, e.g. adenovirus-35, or a modified poxvirus such 
as modified vaccinia virus, to deliver antigens. Genetic modification 
of the viruses renders them replication-deficient and avirulent, and 
allows expression of the mycobacterial antigens to which the immune 
system reacts.
Subunit boost vaccines contain selected mycobacterial antigens, 
together with an adjuvant which delivers antigens in a stable 
formulation, stimulates the immune system for enhancing response 
to the antigen, and steers the immune response in the appropriate 
protective direction. The viruses of viral-vectored vaccines could also 
be viewed as adjuvants.
Most current vaccines contain antigens that are widely recognised 
by immune systems of persons latently infected or diseased with 
MTB, e.g. Ag85A, Ag85B and TB10.4. The dominance of the immune 
response to these antigens is thought to indicate a role in protection. 
It has recently been shown that some antigens may be preferentially 
expressed during latency, compared with early MTB infection or 
disease. Therefore, vaccine candidates developed to specifically 
target latency contain these co-called latency-associated antigens, e.g. 
Rv2660c in a vaccine termed H56.6
Vaccine testing typically involves phase I - IIa trials that focus on 
safety and immunogenicity, first in small groups of healthy adults, 
followed by studies in younger persons and in those with latent TB 
infection and/or HIV infection. Thereafter, phase IIb and III trials 
focus on efficacy to prevent TB disease, and involve much larger 
groups of participants.
SATVI has conducted clinical trials of 5 new TB vaccine 
candidates,6-8 in 11 different protocols. In early trials, 2 viral-vectored 
vaccines, MVA85A and Aeras-402, as well as adjuvanted subunit 
vaccines, H4 and M72, were shown to be safe and immunogenic in 
various populations.7,8 A current trial of H56 is the first in humans. 
Because we have experience of testing multiple vaccine candidates, 
we have been able to observe unique patterns of adverse events and 
of immune induction, depending on the candidate vaccine. These 
comparative data are important for deciding which candidates should 
enter later-phase clinical trials.
We are currently conducting early efficacy trials (phase IIb) of 2 
candidates, MVA85A and Aeras-402, in infants. The results of the 
trial of MVA85A, involving 2 797 infants, and conducted exclusively 
at SATVI, are expected to be available at the beginning of 2013.
Complementary research: critical 
questions in TB vaccine development
As a principle, SATVI uses registration-standard vaccine trials to 
explore other critical areas in vaccine development. These include, 
for example, novel approaches to informed consent,9 tools to measure 
the tuberculin skin test,10 approaches to diagnosing TB disease in 
children for late-phase vaccine trials,11 and detailed studies of the 
vaccination-induced immune response.7,12,13 In addition, specific 
clinical studies have been conducted to address additional questions 
(highlighted below).
Studies to define the TB epidemic
Infants and adolescents are potential target groups for novel TB 
vaccines. Successful conduct of late-phase trials in these populations 
requires reliable data about the TB epidemic at a target site. Since 
data from public health structures are often suboptimal, we have 
completed 2 large-scale epidemiological studies.
A longitudinal study involving 4 786 neonates showed that the 
incidence in children under 2 years of age was 1.5/100 person-years. 
We also wished to address whether active or passive follow-up is 
required for case-finding in efficacy trials: we showed that after 2 
years of follow-up, quarterly home visits, combined with community-
wide surveillance, detected significantly more cases, and at younger 
ages, compared with surveillance with only a single visit at the end 
of the study.14
The ‘Adolescent cohort study’ involved 6 363 adolescents, who 
were followed up for 2 years. We showed an incidence rate of 0.45 
(95% CI 0.30 - 0.69) per 100 person-years. Black or coloured race, 
male gender, older age, household TB contact, low income and low 
education level were significant predictive factors for TB infection. In 
contrast to findings in infants, active surveillance did not significantly 
improve case detection.15
Immunity induced by BCG in HIV-infected infants
Our early studies focused on practical and rigorous methods for 
conducting sophisticated human immunology studies in rural field 
settings.16 These methods were further optimised for paediatric 
applications, such as studies aimed at gaining a better understanding 
of how our immune system interacts with MTB and BCG. We also 
applied this technology to evaluate immunogenicity of BCG in 
HIV-infected children: at the time that this study17 commenced, 
early antiretroviral therapy was not available for this population, 
and reports of complications from the vaccine (BCGosis) emerged. 
We showed that BCG induces very poor immunity in HIV-infected 
infants, both quantitatively and qualitatively,17 and have contributed 
to rational international policy regarding the use of BCG vaccination 
in HIV-infected infants.
Biomarker studies
SATVI’s flagship immunology projects address the holy grail of 
vaccine development – immune correlates of protection against TB. 
Identification of such correlates would accelerate the screening of 
new, better vaccine candidates. Identification of prospective correlates 
of risk of TB disease would also accelerate vaccine development, by 
allowing smaller sample sizes in expensive late-phase trials, through 
targeted enrolment.
We used the ‘BCG Trial’, mentioned above, to determine correlates 
of risk of TB disease, following newborn vaccination with BCG. 
Host responses in blood stored from 10 weeks after newborn BCG 
vaccination were compared in infants who ultimately developed TB 
disease, and those who did not. As we know that T-cell immunity 
is important for protection, our first focus was on these responses. 
Remarkably, we have shown that this immunity, the most commonly 
measured in trials of new TB vaccines, did not correlate with 
risk of TB disease.18 Follow-up studies are focusing on unbiased 
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approaches, such as whole-genome expression analysis, to identify 
novel correlates of risk of TB disease.
Cutting-edge unbiased analyses, such as RNA sequencing, are 
currently being used to determine correlates of risk of TB disease 
in samples from the ‘Adolescent cohort study’. In a similar case-
control design, blood products stored at 6-monthly intervals from 
adolescents who have developed TB disease, and those who have not, 
are being examined.
A definitive study of correlates of protection against TB disease is 
ultimately possible from our randomised controlled phase IIb trials, 
once efficacy has been shown.
The performance of the QuantiFERON test in adolescents
One of the aims of the ‘Adolescent cohort study’ was to evaluate the 
performance of the QuantiFERON Gold-In Tube test (QFT) in a 
TB-endemic setting. This interferon-γ release assay was developed 
as a replacement for the tuberculin skin test (TST), more commonly 
known as the ‘Mantoux test’; both tests indicate the presence of 
latent MTB infection. Unlike the TST, the QFT requires a single 
visit only and is not affected by BCG vaccination or boosted by 
repeated testing. However, the QFT is more costly and requires 
some laboratory infrastructure. We completed more than 20 000 
longitudinal QFT tests in the ‘Adolescent cohort study’. We learned 
about variation in the QFT, and found good agreement between the 
QFT and TST, both of which proved good predictors of the onset of 
TB disease.19 Importantly, we showed that the TST does not need to 
be replaced by the QFT in a high-burden setting such as South Africa. 
Alignment with key stakeholders
Academic collaborations
A major contributor to SATVI’s success has been productive 
partnerships with relevant local and international academics. 
Our contribution has focused on what South Africa can do, and 
does extremely well – enrolling relevant participant populations, 
conducting high-quality clinical research, and bridging the gap 
from the participant to the laboratory bench. We have worked with 
partners to complement these areas in choosing, for example, not 
to set up high-throughput gene expression analysis locally, instead 
deferring that task to well-resourced laboratories overseas. 
An example of a very successful partnership is the TB Vaccine 
Site Network (TBVACSIN), spearheaded by SATVI academics, with 
support from the Aeras Foundation and the European Developing 
Countries Clinical Trials Partnership (EDCTP). This collaboration 
involves a number of African sites, which work towards optimal and 
harmonised TB vaccine trial capacity. Aspects that are addressed 
include training, good clinical and laboratory practice, quality 
management, clinical and microbiological diagnosis of TB, and 
vaccine trial immunology. 
Two other consortia, involving a total of 16 African and Northern 
research groups and funded by the Gates Foundation, under its 
Challenges in Global Health umbrella, have been examples of 
successful collaborations to address specific scientific questions. The 
aim of the first has been to develop a post-infection vaccine: the 
developed vaccine, H56, is currently in a clinical trial at SATVI. The 
other has aimed to develop biomarkers of TB – all samples have been 
collected, and plans for analysis are underway.
Community and health authorities
Successful site development emphasises the importance of community 
engagement and community involvement. A community advisory 
board has served as a voice for the local community, guiding us in 
our research initiatives. We have also learned about the importance of 
community outreach events, and optimal communications through 
local media. Multiple benefits for the relatively socio-economically 
compromised community have emerged from the site’s operations, 
including facilitated and improved healthcare, and a decreased 
incidence of severe forms of TB in infancy.
Political and practical support from the Departments of Health, 
Science and Technology, Education, and Social Development has 
also been critical for success. Involvement on all levels is important 
– from national ministers to national, provincial and district health 
departments. SATVI has had a strong social commitment to the local 
authorities, by providing TB-specific training of health professionals 
and infrastructure development, and by donating equipment to 
health facilities and schools. In turn, local authorities and schools 
have facilitated communication with participants about study end-
points (e.g. TB disease) reached by our study participants, and have 
donated space for our study procedures. We have shown that it is 
possible to design protocols and conduct projects that are mutually 
beneficial for investigators and service providers (and, indirectly, for 
sponsors).
Our most valuable resource – our 
personnel
Our research teams now include experts in clinical trial science, 
epidemiology, clinical aspects and immunology of TB and of vaccines, 
laboratory technology, training, quality assurance and quality control, 
regulation, information technology, data management, finance, 
administration and logistics.
Multiple postgraduate students are training within SATVI. In 
addition to formal academic learning, non-traditional training at 
our site was needed, as persons with specialised skills are in relative 
short supply. SATVI, in collaboration with the Aeras Foundation, 
developed a Professional Development Programme (PDP) to address 
these needs. As a result, each personnel member’s training has been 
tailored to complement his/her brought experience, while addressing 
standards mandated by our research. The PDP has since been shared 
with other TB vaccine sites in Africa and India. Continued investment 
in our personnel has demanded that we change our approaches as 
new needs arise, or for efficiency. Following the PDP, our emphasis 
is on project-specific training, managed by project co-ordinators. We 
are also developing a formal human culture and capital plan.
Optimal strategy/business structures
As is the common experience of companies during rapid growth, 
SATVI has had to add structures on a relatively ad hoc basis from 
2001 to 2011, to meet ever-increasing demands with the risk, 
however, of a loss of efficiency. In 2011, therefore, we conducted an 
academic and a strategic review, as a result of which SATVI’s new 
strategy is based on sustainability, needs in the research environment, 
and a careful assessment of market forces. A new vision and mission 
has been devised, along with strategic objectives and a business plan, 
for the years ahead. This process will mark the transition of SATVI 
from ‘adolescence’ to ‘adulthood’.
Conclusion
We are far from winning the war against TB. The emergence of 
extensively (and totally) drug-resistant MTB strains has highlighted 
the urgency for the development of better vaccines able to prevent 
all forms of the disease. A decade or two ago, prospects for a new TB 
vaccine were dim because many basic questions remain unanswered, 
but the last 10 years have seen rapid development. SATVI has made 
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major contributions to TB vaccine development, and is committed to 
continue to work to achieve ‘A World Without TB’.
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